Combination early-phase trials of anticancer agents in children and adolescents
PURPOSE - - There is an increasing need to evaluate innovative drugs for childhood cancer using combination strategies. Strong biological rationale and clinical experience suggest that multiple agents will be more efficacious than monotherapy for most diseases and may overcome resistance mechanisms...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
June 20, 2023
|
| In: |
Journal of clinical oncology
Year: 2023, Volume: 41, Issue: 18, Pages: 3408-3422 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.22.02430 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.22.02430 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.22.02430 
|
| Author Notes: | Lucas Moreno, Steven G. DuBois, Julia Glade Bender, Audrey Mauguen, Nick Bird, Vickie Buenger, Michela Casanova, François Doz, Elizabeth Fox, Lia Gore, Douglas S. Hawkins, Shai Izraeli, David T.W. Jones, Pamela R. Kearns, Jan J. Molenaar, Karsten Nysom, Stefan Pfister, Gregory Reaman, Malcolm Smith, Brenda Weigel, Gilles Vassal, Christian Michel Zwaan, Xavier Paoletti, Alexia Iasonos, and Andrew D.J. Pearson |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1862659354 | ||
| 003 | DE-627 | ||
| 005 | 20240307050559.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231012s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.22.02430 |2 doi | |
| 035 | |a (DE-627)1862659354 | ||
| 035 | |a (DE-599)KXP1862659354 | ||
| 035 | |a (OCoLC)1425210505 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Moreno, Lucas |e VerfasserIn |0 (DE-588)1305836715 |0 (DE-627)1862659834 |4 aut | |
| 245 | 1 | 0 | |a Combination early-phase trials of anticancer agents in children and adolescents |c Lucas Moreno, Steven G. DuBois, Julia Glade Bender, Audrey Mauguen, Nick Bird, Vickie Buenger, Michela Casanova, François Doz, Elizabeth Fox, Lia Gore, Douglas S. Hawkins, Shai Izraeli, David T.W. Jones, Pamela R. Kearns, Jan J. Molenaar, Karsten Nysom, Stefan Pfister, Gregory Reaman, Malcolm Smith, Brenda Weigel, Gilles Vassal, Christian Michel Zwaan, Xavier Paoletti, Alexia Iasonos, and Andrew D.J. Pearson |
| 264 | 1 | |c June 20, 2023 | |
| 300 | |a 16 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 04. April 2023 | ||
| 500 | |a Gesehen am 12.10.2023 | ||
| 520 | |a PURPOSE - - There is an increasing need to evaluate innovative drugs for childhood cancer using combination strategies. Strong biological rationale and clinical experience suggest that multiple agents will be more efficacious than monotherapy for most diseases and may overcome resistance mechanisms and increase synergy. The process to evaluate these combination trials needs to maximize efficiency and should be agreed by all stakeholders. - - METHODS - - After a review of existing combination trial methodologies, regulatory requirements, and current results, a consensus among stakeholders was achieved. - - RESULTS - - Combinations of anticancer therapies should be developed on the basis of mechanism of action and robust preclinical evaluation, and may include data from adult clinical trials. The general principle for combination early-phase studies is that, when possible, clinical trials should be dose- and schedule-confirmatory rather than dose-exploratory, and every effort should be made to optimize doses early. Efficient early-phase combination trials should be seamless, including dose confirmation and randomized expansion. Dose evaluation designs for combinations depend on the extent of previous knowledge. If not previously evaluated, limited evaluation of monotherapy should be included in the same clinical trial as the combination. Randomized evaluation of a new agent plus standard therapy versus standard therapy is the most effective approach to isolate the effect and toxicity of the novel agent. Platform trials may be valuable in the evaluation of combination studies. Patient advocates and regulators should be engaged with investigators early in a proposed clinical development pathway and trial design must consider regulatory requirements. - - CONCLUSION - - An optimized, agreed approach to the design and evaluation of early-phase pediatric combination trials will accelerate drug development and benefit all stakeholders, most importantly children and adolescents with cancer. | ||
| 700 | 1 | |a DuBois, Steven G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Glade Bender, Julia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mauguen, Audrey |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bird, Nick |e VerfasserIn |4 aut | |
| 700 | 1 | |a Buenger, Vickie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Casanova, Michela |e VerfasserIn |4 aut | |
| 700 | 1 | |a Doz, François |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fox, Elizabeth |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gore, Lia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hawkins, Douglas S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Izraeli, Shai |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jones, David T. W. |e VerfasserIn |0 (DE-588)1058669672 |0 (DE-627)79739334X |0 (DE-576)414823583 |4 aut | |
| 700 | 1 | |a Kearns, Pamela R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Molenaar, Jan J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nysom, Karsten |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pfister, Stefan |d 1974- |e VerfasserIn |0 (DE-588)123850215 |0 (DE-627)706450930 |0 (DE-576)293908400 |4 aut | |
| 700 | 1 | |a Reaman, Gregory |e VerfasserIn |4 aut | |
| 700 | 1 | |a Smith, Malcolm |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weigel, Brenda |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vassal, Gilles |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zwaan, Christian Michel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Paoletti, Xavier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Iasonos, Alexia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pearson, Andrew D.J. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 41(2023), 18 vom: Juni, Seite 3408-3422 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Combination early-phase trials of anticancer agents in children and adolescents |
| 773 | 1 | 8 | |g volume:41 |g year:2023 |g number:18 |g month:06 |g pages:3408-3422 |g extent:16 |a Combination early-phase trials of anticancer agents in children and adolescents |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.22.02430 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.22.02430 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20231012 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 123850215 |a Pfister, Stefan |m 123850215:Pfister, Stefan |d 910000 |d 910500 |e 910000PP123850215 |e 910500PP123850215 |k 0/910000/ |k 1/910000/910500/ |p 17 | ||
| 998 | |g 1058669672 |a Jones, David T. W. |m 1058669672:Jones, David T. W. |d 50000 |e 50000PJ1058669672 |k 0/50000/ |p 13 | ||
| 999 | |a KXP-PPN1862659354 |e 4385628920 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Online veröffentlicht: 04. April 2023","Gesehen am 12.10.2023"],"language":["eng"],"person":[{"given":"Lucas","display":"Moreno, Lucas","family":"Moreno","role":"aut"},{"given":"Steven G.","display":"DuBois, Steven G.","family":"DuBois","role":"aut"},{"given":"Julia","display":"Glade Bender, Julia","family":"Glade Bender","role":"aut"},{"given":"Audrey","role":"aut","family":"Mauguen","display":"Mauguen, Audrey"},{"given":"Nick","display":"Bird, Nick","family":"Bird","role":"aut"},{"given":"Vickie","display":"Buenger, Vickie","family":"Buenger","role":"aut"},{"given":"Michela","family":"Casanova","role":"aut","display":"Casanova, Michela"},{"display":"Doz, François","family":"Doz","role":"aut","given":"François"},{"given":"Elizabeth","family":"Fox","role":"aut","display":"Fox, Elizabeth"},{"display":"Gore, Lia","family":"Gore","role":"aut","given":"Lia"},{"display":"Hawkins, Douglas S.","role":"aut","family":"Hawkins","given":"Douglas S."},{"family":"Izraeli","role":"aut","display":"Izraeli, Shai","given":"Shai"},{"family":"Jones","role":"aut","display":"Jones, David T. W.","given":"David T. W."},{"given":"Pamela R.","display":"Kearns, Pamela R.","family":"Kearns","role":"aut"},{"given":"Jan J.","family":"Molenaar","role":"aut","display":"Molenaar, Jan J."},{"display":"Nysom, Karsten","family":"Nysom","role":"aut","given":"Karsten"},{"role":"aut","family":"Pfister","display":"Pfister, Stefan","given":"Stefan"},{"role":"aut","family":"Reaman","display":"Reaman, Gregory","given":"Gregory"},{"given":"Malcolm","display":"Smith, Malcolm","family":"Smith","role":"aut"},{"family":"Weigel","role":"aut","display":"Weigel, Brenda","given":"Brenda"},{"given":"Gilles","family":"Vassal","role":"aut","display":"Vassal, Gilles"},{"display":"Zwaan, Christian Michel","family":"Zwaan","role":"aut","given":"Christian Michel"},{"display":"Paoletti, Xavier","family":"Paoletti","role":"aut","given":"Xavier"},{"display":"Iasonos, Alexia","role":"aut","family":"Iasonos","given":"Alexia"},{"display":"Pearson, Andrew D.J.","role":"aut","family":"Pearson","given":"Andrew D.J."}],"recId":"1862659354","id":{"eki":["1862659354"],"doi":["10.1200/JCO.22.02430"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"June 20, 2023"}],"name":{"displayForm":["Lucas Moreno, Steven G. DuBois, Julia Glade Bender, Audrey Mauguen, Nick Bird, Vickie Buenger, Michela Casanova, François Doz, Elizabeth Fox, Lia Gore, Douglas S. Hawkins, Shai Izraeli, David T.W. Jones, Pamela R. Kearns, Jan J. Molenaar, Karsten Nysom, Stefan Pfister, Gregory Reaman, Malcolm Smith, Brenda Weigel, Gilles Vassal, Christian Michel Zwaan, Xavier Paoletti, Alexia Iasonos, and Andrew D.J. Pearson"]},"relHost":[{"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"313116962","physDesc":[{"extent":"Online-Ressource"}],"part":{"volume":"41","text":"41(2023), 18 vom: Juni, Seite 3408-3422","issue":"18","pages":"3408-3422","year":"2023","extent":"16"},"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"pubHistory":["1.1983 -"],"corporate":[{"display":"American Society of Clinical Oncology","role":"isb"}],"origin":[{"publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedDisp":"1983-","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","dateIssuedKey":"1983"}],"disp":"Combination early-phase trials of anticancer agents in children and adolescentsJournal of clinical oncology","id":{"issn":["1527-7755"],"eki":["313116962"],"zdb":["2005181-5"]},"title":[{"title":"Journal of clinical oncology","title_sort":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal"}]}],"physDesc":[{"extent":"16 S."}],"title":[{"title":"Combination early-phase trials of anticancer agents in children and adolescents","title_sort":"Combination early-phase trials of anticancer agents in children and adolescents"}]} | ||
| SRT | |a MORENOLUCACOMBINATIO2020 | ||